062-Tumour-intrinsic resistance to ICB
This review article explores tumor-intrinsic factors that lead to resistance against immune checkpoint blockade in cancer treatment. It highlights how the genetic, transcriptional, and functional profiles of tumor cells significantly influence the effectiveness of immunotherapies like those targeting CTLA4 or PD1–PD-L1. The authors discuss several molecular mechanisms of resistance, including insufficient tumor antigenicity, impaired interferon signaling pathways, loss of MHC molecule expression, and the impact of various oncogenic signaling pathways (such as WNT–β-catenin, CDK4–CDK6, MAPK…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.